Congestive heart failure treatment of patients at high risk for developing heart failure (Stage A): Difference between revisions
No edit summary |
No edit summary |
||
Line 41: | Line 41: | ||
9. Healthcare providers should perform a noninvasive evaluation of [[LV function]] (i.e., [[LVEF]]) in patients with a strong family history of [[cardiomyopathy]] or in those receiving cardiotoxic interventions. ''(Level of Evidence: C)'' | 9. Healthcare providers should perform a noninvasive evaluation of [[LV function]] (i.e., [[LVEF]]) in patients with a strong family history of [[cardiomyopathy]] or in those receiving cardiotoxic interventions. ''(Level of Evidence: C)'' | ||
===Class IIa=== | |||
1. [[Angiotensin converting enzyme inhibitors]] can be useful to prevent [[HF]] in patients at high risk for developing [[HF]] who have a history of [[atherosclerotic vascular disease]], [[diabetes mellitus]], or [[hypertension]] with associated cardiovascular risk factors. ''(Level of Evidence: A)'' | |||
2. [[Angiotensin II receptor blockers]] can be useful to prevent [[HF]] in patients at high risk for developing [[HF]] who have a history of [[atherosclerotic vascular disease]], [[diabetes mellitus]], or [[hypertension]] with associated cardiovascular risk factors. ''(Level of Evidence: C)'' | |||
==See Also== | ==See Also== |
Revision as of 18:46, 9 June 2009
Heart failure | |
ICD-10 | I50.0 |
---|---|
ICD-9 | 428.0 |
DiseasesDB | 16209 |
MedlinePlus | 000158 |
eMedicine | med/3552 |
MeSH | D006333 |
WikiDoc Resources for Congestive heart failure treatment of patients at high risk for developing heart failure (Stage A) |
Articles |
---|
Media |
Evidence Based Medicine |
Clinical Trials |
|
Guidelines / Policies / Govt |
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
|
Healthcare Provider Resources |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Cardiology Network |
Discuss Congestive heart failure treatment of patients at high risk for developing heart failure (Stage A) further in the WikiDoc Cardiology Network |
Adult Congenital |
---|
Biomarkers |
Cardiac Rehabilitation |
Congestive Heart Failure |
CT Angiography |
Echocardiography |
Electrophysiology |
Cardiology General |
Genetics |
Health Economics |
Hypertension |
Interventional Cardiology |
MRI |
Nuclear Cardiology |
Peripheral Arterial Disease |
Prevention |
Public Policy |
Pulmonary Embolism |
Stable Angina |
Valvular Heart Disease |
Vascular Medicine |
Template:WikiDoc Cardiology News Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview of Clinical Assessment of Congestive Heart Failure
ACC / AHA Guidelines- Initial Clinical Assessment of Patients Presenting With HF (DO NOT EDIT) [1]
{{cquote|
Class I
1. In patients at high risk for developing HF, systolic and diastolic hypertension should be controlled in accordance with contemporary guidelines. (Level of Evidence: A)
2. In patients at high risk for developing HF, lipid disorders should be treated in accordance with contemporary guidelines. (Level of Evidence: A)
3. For patients with diabetes mellitus (who are all at high risk for developing HF), blood sugar should be controlled in accordance with contemporary guidelines. (Level of Evidence: C)
4. Patients at high risk for developing HF should be counseled to avoid behaviors that may increase the risk of HF (e.g., smoking, excessive alcohol consumption, and illicit drug use). (Level of Evidence: C)
5. Ventricular rate should be controlled or sinus rhythm restored in patients with supraventricular tachyarrhythmias who are at high risk for developing HF. (Level of Evidence: B)
6. Thyroid disorders should be treated in accordance with contemporary guidelines in patients at high risk for developing HF. (Level of Evidence: C)
7. Healthcare providers should perform periodic evaluation for signs and symptoms of HF in patients at high risk for developing HF. (Level of Evidence: C)
8. In patients at high risk for developing HF who have known atherosclerotic vascular disease, healthcare providers should follow current guidelines for secondary prevention. (Level of Evidence: C)
9. Healthcare providers should perform a noninvasive evaluation of LV function (i.e., LVEF) in patients with a strong family history of cardiomyopathy or in those receiving cardiotoxic interventions. (Level of Evidence: C)
Class IIa
1. Angiotensin converting enzyme inhibitors can be useful to prevent HF in patients at high risk for developing HF who have a history of atherosclerotic vascular disease, diabetes mellitus, or hypertension with associated cardiovascular risk factors. (Level of Evidence: A)
2. Angiotensin II receptor blockers can be useful to prevent HF in patients at high risk for developing HF who have a history of atherosclerotic vascular disease, diabetes mellitus, or hypertension with associated cardiovascular risk factors. (Level of Evidence: C)
See Also
Sources
- The ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult [1]
References
- ↑ 1.0 1.1 Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American College of Chest Physicians; International Society for Heart and Lung Transplantation; Heart Rhythm Society. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005 Sep 20; 112(12): e154-235. Epub 2005 Sep 13. PMID 16160202